AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Biomarkers for Alzheimer's Disease Diagnosis

Detailed Technology Description
CornellResearchers have identified a set of Alzheimer's disease-specific proteinbiomarkers that can be used in the analysis of cerebrospinal fluid (CSF) todiagnose Alzheimer's disease (AD) patients.
Others
  • U.S. Patent 9,335,331
  • Choi Y,Choe LH, Lee KH (2010). Recent cerebrospinal fluid biomarker studies ofAlzheimer's disease. Expert Review ofProteomics 7: 919-926. PMID: 21142892. DOI: 10.1586/epr.10.75
  • FinehoutE.J., et al. (2007). Cerebrospinal Fluid Proteomic Biomarkers for Alzheimer'sDisease. Annals of Neurology 61,120-129. DOI: 10.1002/ana.21038
  • Choe L,et al. (2007). 8-Plex quantitation of changes in cerebrospinal fluid proteinexpression in subjects undergoing intravenous immunoglobulin treatment forAlzheimer’s disease. Proteomics7(20):3651-3660. DOI: 10.1002/pmic.200700316.
*Abstract

Alzheimer’s disease is the leadingcause of dementia amongst the elderly, yet a diagnosis cannot be made until theonset of the disease.  According to the Alzheimer’sAssociation, in 2016 an estimated 5.2 million of American people age 65 andolder have Alzheimer's disease and the number are projected to reach 13.8million by 2050.  Early detection of ADis essential to a holistic management of the disease (medication to delay theprogress, health care cost, etc.). 

 

The technology developed by Cornellresearchers allows for an early diagnostic of AD and comprises:

  1. A panelof specific multiplexed biomarkers in CSF that could be used to quantitativelydifferentiate between samples from AD patients and from non-AD patients
  2.  An associated database with information onprotein expression levels that are and are not associated with AD.

 

Thistechnology enables early detection of AD, thus allows for adequate treatment strategies. It has been tested together with aclinical trial of AD therapeutics.  Apanel of 23 spots was identified that could be used to differentiate AD andnon-AD gels with a sensitivity of 94%, a specificity of 94%, and a predictedclassification error rate of only 5.9%. The figure below. shows the abilityof the biomarkers panel to isolate AD from non-AD patients amongst 68 cerebrospinal fluid samples).

 

 

PotentialApplications

Earlydiagnostic test for Alzheimer's disease.

 

Advantages

  • Anearly diagnostic test would eliminate false positives, allowing doctors toexplore disease possibilities other than AD.
  • Thisdiagnostic method is comprehensive, compared to existing methods that mustemploy several different tests to detect AD.
  • Thediagnostics can be done using ELISA and other techniques.

  
*Licensing
Phillip Owh607-254-4508po62@cornell.edu
Country/Region
USA

For more information, please click Here
Mobile Device